0000899243-22-039331.txt : 20221223 0000899243-22-039331.hdr.sgml : 20221223 20221223200019 ACCESSION NUMBER: 0000899243-22-039331 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20221110 FILED AS OF DATE: 20221223 DATE AS OF CHANGE: 20221223 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Josephson Neil CENTRAL INDEX KEY: 0001864141 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-41535 FILM NUMBER: 221486647 MAIL ADDRESS: STREET 1: 114 EAST 4TH AVENUE, SUITE 800 CITY: VANCOUVER STATE: A1 ZIP: V5T 1G4 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Zymeworks Inc. CENTRAL INDEX KEY: 0001937653 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 108 PATRIOT DRIVE, SUITE A CITY: MIDDLETOWN STATE: DE ZIP: 19709 BUSINESS PHONE: 206-337-1030 MAIL ADDRESS: STREET 1: 108 PATRIOT DRIVE, SUITE A CITY: MIDDLETOWN STATE: DE ZIP: 19709 FORMER COMPANY: FORMER CONFORMED NAME: Zymeworks Delaware Inc. DATE OF NAME CHANGE: 20220712 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2022-11-10 2022-11-14 0 0001937653 Zymeworks Inc. ZYME 0001864141 Josephson Neil C/O ZYMEWORKS INC. 108 PATRIOT DRIVE, SUITE A MIDDLETOWN DE 19709 0 1 0 0 Chief Medical Officer Common Stock 2022-11-10 4 M 0 5885 0.00 A 16924 D Common Stock 2022-11-10 4 S 0 2475 8.099 D 14449 D Restricted Stock Unit 2022-11-10 4 M 0 5885 0.00 D Common Shares 5885 11772 D Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on November 10, 2021. Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs. Pursuant to the terms of the applicable RSU grant agreement (the "Grant Agreement"), effective on the grant date of the RSUs, the Reporting Person adopted a 10b5-1 plan pursuant to which the Reporting Person elected to sell shares to cover tax withholding obligations and other applicable fees in accordance with the terms of the Grant Agreement. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.09 to $8.10, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The RSUs were granted on November 10, 2021 and vest in three equal annual instalments beginning on November 10, 2022. This Amendment is being filed solely to include Exhibit 24 - Power of Attorney, which was inadvertently omitted in the Form 4 filed on November 14, 2022. Exhibit List - Exhibit 24 - Power of Attorney. On October 13, 2022, the Issuer (formerly Zymeworks Delaware Inc., a Delaware corporation) became the successor issuer of Zymeworks BC Inc. (formerly Zymeworks Inc., a corporation continued under the Business Corporations Act (British Columbia)) pursuant to Rule 12g-3 of the Securities Exchange Act of 1934, as amended. On such date the Issuer completed a series of transactions, including a redomicile, pursuant to a statutory plan of arrangement under Section 288 of the Business Corporations Act (British Columbia), as a result of which common shares of Zymeworks BC Inc. were exchanged for either shares of common stock of the Issuer or exchangeable shares issued by Zymeworks ExchangeCo Ltd., an indirect subsidiary of the Issuer. /s/ Daniel Dex, Attorney-in-Fact 2022-12-23 EX-24 2 attachment1.htm EX-24 DOCUMENT

                                                                      Exhibit 24

                               POWER OF ATTORNEY

     The undersigned, as a Section 16 reporting person of Zymeworks Delaware
Inc. (the "Company"), hereby constitutes and appoints Daniel Dex and each of the
responsible attorneys and paralegals of Wilson Sonsini Goodrich & Rosati,
Professional Corporation, the undersigned's true and lawful attorney-in-fact to:

     1. complete and execute Forms ID, 3,4 and 5 and other forms and all
        amendments thereto as such attorney-in-fact shall in his or her
        discretion determine to be required or advisable pursuant to Section 16
        of the Securities Exchange Act of 1934 (as amended) and the rules and
        regulations promulgated thereunder, or any successor laws and
        regulations, as a consequence of the undersigned's ownership,
        acquisition or disposition of securities of the Company; and

     2. do all acts necessary in order to file such forms with the Securities
        and Exchange Commission, any securities exchange or national
        association, the Company and such other person or agency as the
        attorney-in-fact shall deem appropriate.

     The undersigned hereby ratifies and confirms all that said
attorneys-in-fact and agents shall do or cause to be done by virtue hereof.  The
undersigned acknowledges that the foregoing attorneys-in-fact, in serving in
such capacity at the request of the undersigned, are not assuming, nor is the
Company assuming, any of the undersigned's responsibilities to comply with
Section 16 of the Securities Exchange Act of 1934 (as amended).

     This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms ID, 3, 4 and 5 with respect to
the undersigned's holdings of and transactions in securities issued by the
Company, unless earlier revoked by the undersigned in a signed writing delivered
to the Company and the foregoing attorneys-in-fact.

     IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of July 12, 2022.



                                Signature: /s/ Neil Josephson
                                           ------------------